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Antisense oligonucleotides and short interfering RNAs (siR-
NAs) are nucleic acids-targeting reagents for gene expres-
sion modulation that are being developed as drugs for many 
applications.  A  number  of  useful  synthetic  nucleic  acids 
analogues have been introduced recently to greatly improve 
their properties for use as therapeutics. However, their full 
effectiveness in cells and in vivo has often only been real-
ized through development of suitable nonviral delivery sys-
tems. Among these, a range of natural and synthetic peptides 
have been found useful for enhancing cellular uptake and/or 
cell targeting of oligonucleotide analogues and siRNA. Such 
peptides are synthetically conjugated, used as noncovalent 
complexes, or used in combination with polymer, liposomal 
or exosome formulation techniques. This review begins by 
describing the modes of action of antisense reagents and 
siRNA  and  goes  on  to  focus  on  recent  advances  in  their 
peptide-mediated cell and in vivo delivery and how peptide 
use has influenced drug development. The review discusses 
the challenges associated with understanding the physiologi-
cal and toxicological aspects of peptide-mediated delivery. 
Developments towards clinical use are also highlighted, with 
particular emphasis on peptide conjugates of oligonucleotide 
analogues used for treatment of neuromuscular diseases.
INTRODUCTION
Antisense oligonucleotides are used widely to interfere with 
biological  processes  in  cells  and  are  being  developed  in 
some cases as drugs.1,2 There are numerous types of oligo-
nucleotide analogue of varying chemistries, as well as short 
interfering RNAs (siRNAs), and they encompass a range of 
intracellular targets and modes of action. Common to all oli-
gonucleotide types is the need to be delivered into cells and 
tissues efficiently in order to carry out their targeting func-
tions. Some types are able to enter certain cell classes in vivo 
(such as hepatocytes or kidney cells) reasonably efficiently 
in naked form (e.g., those containing both phosphorothioate 
(PS) linkages and certain sugar modifications),3 but bio-avail-
ability at the right cellular location may still be limited by poor 
cell trafficking and endosomal entrapment. In other cell types, 
cell targeting and entry is found to be poor for many naked 
oligonucleotide types, or their ability to reach the desired tis-
sue is limited. Accordingly, there have been massive efforts 
to search for new delivery systems that may enhance tissue 
penetration, improve cell targeting and cell entry, as well as 
enhance intracellular bioavailability at the desired biological 
target. The most prevalent delivery systems for oligonucle-
otides and siRNA are cationic liposomes and other nanopar-
ticle delivery systems, based initially on cell culture studies 
and later translated into sophisticated multicomponent in vivo 
vectors.4,5
Among  the  simpler  methods  that  have  been  utilized  to 
enhance  cell  delivery  of  oligonucleotides  and  siRNA  are 
cationic peptide vectors, often referred to as cell-penetrating 
peptides  (CPPs)  or  peptide  transduction  domains  (PTDs). 
The first CPP was introduced in 19946 and since then there 
has been a continuous stream of new peptide delivery vectors 
where increased delivery and better pharmacological proper-
ties are claimed and a variety of applications demonstrated.7 
The  cellular  entry  and  intracellular  trafficking  mechanisms 
behind peptide-mediated transduction are still not fully eluci-
dated but are reviewed thoroughly elsewhere.8–11 In addition 
to CPPs, there are peptides designed to target to specific 
cells or tissues (homing peptides).12 This review concentrates 
on recent progress (since 2007) in all of the various peptide-
mediated strategies for delivery of antisense oligonucleotides 
and siRNA into cells in culture and also in in vivo applica-
tions, and points to prospects for clinical development.
MODES OF ACTION OF OLIGONUCLEOTIDE 
AND siRNA THERAPEUTICS
There are several ways that short oligonucleotides and siRNA 
can  affect  cellular  processes,  schematically  illustrated  in 
  Figure 1. The most obvious approach, originally proposed by 
Zamecnik and Stevenson,13 is antisense binding through Wat-
son-Crick base pairing to messenger RNA (mRNA) to block 
translational  initiation  or  elongation  and  thus  decrease  the 
levels of the corresponding protein (Figure 1a). Steric block-
ing of ribosomal elongation is known to be hard to achieve, 
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but blocking of ribosomal initiation can be efficient by targeting 
the initiator AUG region, the 5′-cap region, or, where appro-
priate, an internal ribosome entry site. It is also possible to 
block polyadenylation.14 Such targeting requires delivery of oli-
gonucleotides in stoichiometric amount to that of the targeted 
mRNA present in the cell at a given time. Steric blocking also 
requires the use of strongly binding oligonucleotide analogues 
to ensure good competition for the mRNA with the proteins 
involved in translation or other cellular processes.
Similarly  to  steric-blocking  mRNA  binding,  some  oligo-
nucleotides are also capable of binding in triplex mode to 
certain specific DNA sequences and inhibiting transcription 
in the nucleus, leading to a decrease in mRNA production,15 
but difficulties in obtaining sufficient potency when targeting 
chromosomal DNA selectively make gene expression inhi-
bition  through  triplex  formation  currently  less  attractive  as 
a therapeutic intervention mechanism. However, sequence-
specific gene modification via triplex formation is a new sub-
ject that has recently shown great potential.16
A second mechanism involves antisense binding to RNA 
followed  by  recruitment  and  activation  of  RNase-H,  which 
  consequently  leads  to  degradation  of  the  mRNA  target 
(Figure 1b). This mode of action is limited to those oligonu-
cleotides containing a minimum stretch of 6–10 unmodified 
DNA or PS DNA units (known as gapmers), but outer nucle-
otides  can  be  more  heavily  modified  to  enhance  comple-
mentary RNA binding. In principle, catalytic turnover allows a 
lower concentration of oligonucleotides to be used compared 
to steric-blocking oligonucleotides. RNase-H–dependent anti-
sense has been used very successfully to reduce expression 
levels of specific proteins, or to inhibit viral replication.17,18
In the case of RNA interference, one strand of an siRNA 
duplex  (antisense  or  guide  strand)  becomes  targeted  to 
the mRNA as a result of recruitment by the RNA-induced 
silencing complex (RISC) cellular machinery and leads sub-
sequently to RNA cleavage (Figure 1c). The siRNA can be 
targeted to any accessible part of the mRNA, similar to the 
RNase-H–dependent oligonucleotide targeting method. The 
sense (passenger) strand may include chemically modified 
nucleotides in any position, whereas the antisense strand 
only tolerates a limited range of modified nucleotides in spe-
cific locations.
Single-stranded  oligonucleotide  analogues  have  shown 
great promise as inhibitors of micro-RNA (miRNA) action by 
Figure 1  Schematic illustration of how synthetic oligonucleotides affect cellular processes. (a) Complementary oligonucleotide 
binds to mRNA and sterically blocks translation initiation or elongation. (b) Complementary oligonucleotide binds to mRNA and recruits 
RNase H. (c) siRNA cell internalization leads to one strand binding to mRNA and triggering RISC-dependent RNA cleavage. (d) A comple-
mentary oligonucleotide binds to the sense strand of a miRNA and blocks RISC activation. (e) An oligonucleotide masks the miRNA bind-
ing site on the mRNA and prevents RISC-mediated mRNA degradation or translation inhibition. (f) A splice site is masked on the mRNA, 
which results in exon exclusion. (g) A splice site is masked on the mRNA, which results in exon inclusion. mRNA, messenger RNA; miRNA, 
microRNA; RISC, RNA-induced silencing complex; siRNA, short interfering RNA.
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preventing miRNA binding to mRNA that would otherwise 
trigger the RNA interference machinery and result in mRNA 
downregulation  or  degradation  (Figure  1d).  Interestingly, 
good levels of intracellular activity have been achieved with-
out requiring CPP-assisted delivery both in cell culture and in 
vivo (e.g., for peptide nucleic acid (PNA) and locked nucleic 
acid (LNA)),19,20 in contrast to naked oligonucleotides target-
ing mRNA, where high concentrations and extended periods 
are required in cell culture for RNase-H–dependent activity 
when delivered gymnotically (from Greek: gymnos, mean-
ing naked).21 Oligonucleotides targeting miRNAs have been 
shown to rapidly enter cells and interfere with miRNA activity 
at submicromolar concentrations.19,22 Current thinking is that 
the oligonucleotide may meet the miRNA somewhere within 
the  endosomal  pathway,20  and  therefore  CPP-enhanced 
endosomal release may be unnecessary, although the gen-
erality of this conclusion for all cell types and miRNAs is yet 
to be established. Inhibition of miRNA is thought to occur by 
miRNA sequestration rather than by degradation.20 Therapeu-
tic applications of anti-miRs have been recently reviewed.23 
An alternative mechanism has also proven successful, where 
a short oligonucleotide binds the mRNA to cover the miRNA-
binding site to again prevent RISC binding and subsequent 
mRNA downregulation (Figure 1e).24
Another important mode of action of antisense oligonucle-
otides involves splicing redirection of pre-mRNA in the cell 
nucleus. An oligonucleotide directed to regions at, or close 
to, a splice site can mask normal or aberrant splicing events 
leading either to exon exclusion (Figure 1f) or exon inclusion 
(Figure 1g). Splicing redirection model systems have been 
used very successfully to monitor peptide-mediated oligonu-
cleotide delivery.25,26 In addition, the methodology is already 
being assessed in the clinic for treatment of neuromuscular 
and  neurodegenerative  diseases  where  targeting  of  spe-
cific exons in mutated dystrophin pre-mRNA with antisense 
phosphorodiamidate  morpholino  oligonucleotides  (PMO) 
allows redirection of the splicing pattern to restore a correct 
reading frame (exon skipping), resulting in the regeneration 
of functional dystrophin protein expression.27 Stimulation of 
exon inclusion by antisense oligonucleotides is an alternative 
mechanism being examined for potential treatment for spinal 
muscular atrophy.28 In addition, exon skipping can be applied 
to wild-type genes to generate out-of-frame transcripts as a 
method of normal protein downregulation.29
TYPES OF OLIGONUCLEOTIDE ANALOGUE
In addition to low bioavailability, the poor stabilities of unmodi-
fied DNA and RNA and rapid clearance from the bloodstream 
have been major drawbacks for use as therapeutics. Thus, 
many different oligonucleotide analogues have been devel-
oped in order to increase stability, RNA binding, and other 
therapeutically  useful  properties.  A  selection  of  important 
oligonucleotide analogues that have been involved with pep-
tide-mediated delivery is presented in Figure 2. Each ana-
logue type has particular properties that make them suitable 
for different applications.2,30
Perhaps the most utilized and well-studied analogue is the 
PS linkage where a sulfur atom replaces one non-bridging oxy-
gen atom in the phosphate backbone (Figure 2a). The PS link-
age can be included in any DNA- or RNA-type oligonucleotide 
and increases nuclease resistance, whereas in an otherwise 
unmodified DNA it permits RNase-H activation. Introduction 
of the PS linkage reduces RNA-target affinity somewhat but 
leads to enhanced interaction with plasma proteins, thereby 
decreasing renal clearance rates.31 Despite some concerns 
as to possible toxic side effects at higher concentrations, PS 
linkages are included in all FDA-approved oligonucleotides to 
date, which unfortunately are currently very few.32,33
The 2′-O-methyl nucleotide (2′-OMe), in which a methyl 
group replaces a hydrogen atom in the 2′-hydroxyl group 
in the ribose ring of RNA (Figure 2b), also imparts nucle-
ase resistance, but does not permit RNase-H activation. 
Such  non-RNase-H  inducing  oligonucleotides  are  par-
ticularly valuable in certain applications where the target 
RNA  needs  to  remain  intact  (e.g.,  splicing  redirection). 
Figure 2  A selection of common oligonucleotide analogues delivered by peptide-mediated means. (a) Phosphorothioate (PS) link-
ages, (b) 2′-O-Methyl oligonucleotide (2′-OMe), (c) locked nucleic acid (LNA), (d) Phosphorodiamidate morpholino oligonucleotide (PMO), 
and (e) peptide nucleic acid (PNA).
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Although the 2′-OMe modification is insensitive to endo-
nucleases,  it  is  still  partially  susceptible  to  exonuclease 
degradation. By combining PS linkages and 2′-OMe nucle-
otides  (PS-2′-OMe),  much  greater  in  vivo  stability  has 
been achieved resulting in several successful applications. 
Further  enhancements  of  therapeutic  activity  have  been 
achieved in some cases by including other 2′-O-alkylated 
nucleotides (such as 2′-O-methoxyethyl, MOE) or 2′-fluoro-
2′-deoxynucleotides, resulting in “mixmers”. All these ana-
logues are also used in the wings of gapmers, as well as in 
particular positions of siRNA.
A  highly  successful  nucleotide  analogue  is  LNA,  which 
is a constrained RNA analogue having a methylene bridge 
between the 2′ and 4′ positions in the ribose ring (Figure 2c). 
LNA is also unable to activate RNase-H, but due to the con-
strained backbone LNA has a very high affinity for single-
stranded DNA/RNA compared to other analogues. In addition 
to high affinity, LNAs display high in vivo stability and slower 
renal clearance, although in rare cases hepatotoxicity has 
been  observed.34 The  increased  affinity  allows  LNA  to  be 
used in much shorter oligonucleotide than for many other 
analogue  types  (tiny  LNAs,).35  However,  nonspecific  bind-
ing of longer sequences of LNAs, which could result in off-
target effects, is alleviated by using LNA in combination with 
unmodified DNA or with other analogues, such as 2′-OMe, in 
steric-blocking applications. LNA is also used in RNase-H–
dependent applications in the wings of all PS gapmers where 
the central section is PS-DNA.
A separate class of analogues are charge neutral. In PMO, 
the ribose is replaced by a morpholino moiety and the natural 
phosphodiester linkage is replaced by an uncharged phos-
phorodiamidate  backbone  (Figure  2d).  The  constrained 
structure and the lack of electrostatic repulsion between the 
oligonucleotide and its target both contribute to make PMO–
RNA interactions more stable compared to DNA–RNA inter-
actions. PMO does not activate RNase-H, but it has been 
used  successfully  for  steric  block  antisense  purposes,  in 
many in  vivo  applications  and  in  the  clinic.36,37  Like  PMO, 
PNA is an uncharged oligonucleotide analogue, where the 
sugar-phosphate backbone is replaced by repeating N-(2-
aminoethyl)-glycine  units  linked  together  by  amide  bonds 
(Figure 2e). PNA has very high affinity for DNA/RNA that, 
like PMO, is due partly to the lack of charge repulsion of the 
peptide-like  backbone.  PNAs  display  high  selectivity  and 
mismatch discrimination towards its target strand and have 
been used effectively in many antisense applications and in 
vivo.16,38 Further, PNA containing a few additional cationic 
residues (e.g., lysine) have been used successfully to block 
miRNA  activity  without  the  use  of  a  transfection  agent  or 
delivery peptide.19,20
The  need  for  improved  oligonucleotide  therapies  has 
accelerated  advances  in  chemistry  and  many  newer  ana-
logues have emerged recently. Unfortunately very few have 
been able to attain high stability, affinity, and selectivity, while 
maintaining low toxicity and off-target effects and which are 
available to researchers in sufficient quantities and reliability 
for in vivo studies. The analogues selected for mention in this 
review are those that not only have most of these above attri-
butes but also have been most utilized in peptide-mediated 
delivery.
STRATEGIES FOR PEPTIDE-MEDIATED DELIvERY
There are two main ways of utilizing peptide vectors for the 
delivery of antisense oligonucleotides and siRNA. The first 
method  involves  chemical  synthesis  of  peptides  that  are 
modified to enable covalent conjugation to oligonucleotides 
or other cargo types (Figure 3a). Such conjugation reactions 
may be carried out either on solid support or in solution, and 
often result in high yields. An advantage of covalent conju-
gation is that this results in a well-defined single entity that 
simplifies drug development. Linker types may be chemically 
stable, which ensures that the peptide–oligonucleotide con-
jugate remains intact throughout in vivo administration and 
the subsequent delivery process and that degradation now 
reflects  only  the  proteolytic  susceptibility  of  the  particular 
peptide. There are numerous conjugation strategies, includ-
ing  thioether,  thiol-maleimide,  ester  formation,  and  “click” 
chemistry (reviewed in ref. 39,40).
Alternatively, a labile linker cleavable within the cell, such as 
a disulphide linkage, has proven very successful in studies of 
peptide-mediated delivery, both in cells and in vivo.41,42 Such 
disulphide bridges may remain sufficiently stable, if admin-
istration is rapid, but may be cleaved later when the conju-
gate reaches the reducing environment of the endosome/
cytoplasm. This approach was initially favored in therapeutic 
design, because cleavage diminishes the risk of any detri-
mental effect of the peptide on the interaction of the oligo-
nucleotide with its target. However, recent in vivo applications 
using stable linkages suggest that peptide-cargo cleavage is 
not essential. Recent studies have suggested also that thiol 
or disulfide groups might enhance cellular uptake, although 
the reasons for this are not as yet fully understood.43,44
Although covalent conjugation is very suitable for charge-
neutral oligonucleotide analogues, there are technical diffi-
culties in conjugation and purification of conjugates of highly 
cationic  peptides  with  negatively  charged  oligonucleotides 
that have limited the type of peptide that can be conjugated.45 
Sadly, meaningful comparative data on the effects of differ-
ent peptide-oligonucleotide linkages in biological antisense 
assays are mostly lacking.
The second method of peptide-mediated oligonucleotide 
delivery  exploits  the  complexing  properties  of  CPPs  and 
their  derivatives  (Figure  3b).  For  example,  cationic  CPPs 
can form complexes efficiently with negatively charged oli-
gonucleotides.8 Further, some peptide vectors also contain 
hydrophobic  elements  (hydrophobic  amino  acids  or  addi-
tion of hydrophobic amino acids and/or other moieties such 
as fatty acids, lipids or cholesterol), which are designed for 
complex formation with both negatively charged and charge-
neutral  analogue  types.  Such  complexing  peptides  form 
nanosized particles together with the oligonucleotides that 
are better able to translocate across the plasma membrane 
(in some cases perhaps avoiding the endosomal uptake sys-
tem altogether)46 and can deliver the oligonucleotide cargo to 
the target with greater efficiency.
It is common to optimize empirically the ratio of the peptide 
over cargo to obtain the best cellular delivery. The noncova-
lent strategy does not require the oligonucleotide to be end-
modified for conjugation, and thus complex formation is often 
achieved by simple mixing. Complex formation also results Delivery of Antisense Oligonucleotides
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in protection of the oligonucleotide or siRNA from nuclease 
degradation. On the other hand, structures of varying and 
undefined size may be generated, which complicates drug 
characterization and subsequent in vivo use. In the cases of 
uncharged PMO or PNA, it has been common to first hybrid-
ize to a complementary DNA strand (leash) before complex 
formation with cationic peptide vectors.47
Recently, a new generation of chemically modified peptide 
vectors  for  noncovalent  conjugation  has  been  introduced 
(Figure 3c), based on the original work of Futaki et al. that 
involved  stearylation  of  cationic  poly-arginine  peptides  as 
delivery vectors for plasmid DNA.48 For example, a steary-
lated  peptide  showed  noncovalent  complex  formation  and 
enhanced  cell  delivery  of  a  2′-OMe  splice-redirecting  oli-
gonucleotide.49 It seems that the peptide sequence needs 
to be carefully tuned to the type of cargo as well as to the 
application,  since  for  example  a  stearylated  poly-arginine 
peptide was found to be ineffective in cellular delivery of a 
splice-  correcting oligonucleotide, despite being effective with 
a larger plasmid.
Other nanovectors involve peptides associated with cat-
ionic polymers (Figure 3d) or peptides complexed/cell sur-
face displayed on liposomes or exosomes (Figure 3e). In 
addition to CPPs designed for general enhancement of cell 
entry, peptides can also be used to target specific cell sur-
face receptors or tissues (homing peptides). These can be 
conjugated to an oligonucleotide by themselves (Figure 3a) 
or incorporated as a chimera with a CPP, or embedded on 
the surface of a nanovector (Figure 3f). This last concept 
combines the cell-penetrating or cell-targeting properties of 
a peptide with oligonucleotide or siRNA encapsulation tech-
nology (e.g., liposomes or exosomes) and this has recently 
opened up new possibilities for cell delivery.
Just  as  for  any  type  of  delivery  agent,  the  advantages 
gained over a naked oligonucleotide or siRNA in use of a 
peptide vector (whether conjugate or complex) in enhanc-
ing cell and/or in vivo delivery must outweigh the disadvan-
tages of the additional size of the molecule and the increased 
potential cost per gram. In the case of siRNA, for all except 
kidney and topical applications, it is clear that a complexation 
vector of some sort is required to obtain any significant in vivo 
activity. This is partly because the vector protects the siRNA 
from rapid degradation as well as helps the siRNA to pas-
sage into the cell and be released from endosomes. A simple 
peptide-based complexation vector is attractive compared to 
the better known but more complex lipid-based or polymeric 
nanoparticle vectors in terms of simplicity and cost of com-
ponents. Here the question is more as to whether a peptide 
vector can be found to offer sufficient in vivo delivery power 
or tissue targeting compared to the other more sophisticated 
types of delivery vectors.
By contrast in the case of oligonucleotides, the advantages 
of using a peptide vector are fully dependent on the organ type 
and the application. For liver in vivo applications for example, 
there is already good delivery of naked PS oligonucleotides 
and a peptide vector seems unlikely to add more than a mar-
ginal benefit at best. However, delivery to muscle for example 
with  naked  oligonucleotide  analogues,  including  PMO  and 
PNA,  requires  very  high  dosages  in  animals  to  obtain  any 
activity (see for example the muscular dystrophy applications 
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Figure 3  Schematic illustration of formulation strategies for peptide-mediated oligonucleotide delivery. (a) Covalent conjugation 
between peptide vector and oligonucleotide via a stable or cleavable linker. (b) Complex formation between peptide and oligonucleotides 
through electrostatic and/or hydrophobic interactions. (c) Complex formation between lipid-conjugated peptide and oligonucleotides through 
electrostatic and/or hydrophobic interactions. (d) Oligonucleotide condensation by peptide-functionalized cationic polymers. (e) Lipid vesicle or 
exosome loaded with oligonucleotides and functionalized with a CPP. (f) Lipid vesicle or exosome loaded with oligonucleotides and functional-
ized with a targeting/homing peptide. CPP, cell-penetrating peptide; ON, oligonucleotide; siRNA, short interfering RNA.Molecular Therapy–Nucleic Acids
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described later) and here the substantial improvement in in 
vivo  activity  afforded  by  covalent  peptide  conjugation  eas-
ily outweighs the added cost and effort of conjugation. In the 
examples that follow, readers should bear in mind that there are 
still relatively few peptide vectors currently being considered for 
therapeutic use and few if any publications have addressed 
toxicology, potential immune recognition, or demonstrated cost/
benefit analysis. Most of the vectors describing enhanced cell 
delivery represent therefore research in progress.
PEPTIDE CONJUGATES AND COMPLEXES FOR 
ANTISENSE OLIGONUCLEOTIDE AND siRNA 
APPLICATIONS
Peptide-mediated delivery of RNase-H–dependent antisense 
oligonucleotides into cells in culture was first shown in 1994 
through  covalent  CPP  conjugation.50,51  The  covalent  CPP 
attachment concept was later used for steric-blocking PNA in 
downregulation of the galanin receptor in vivo.41 Since then 
many demonstrations of antisense and siRNA cell delivery by 
CPPs have been published. Tables 1–4 show some recent 
examples. The choice of antisense mechanism or siRNA is 
dependent on the particular application and this in turn influ-
ences the type of peptide delivery system available. In cases 
where the particular RNA target permits a choice of target-
ing methods available, the generally lower potency of ster-
ic-blocking oligonucleotides has to be balanced against the 
greater possibility of off-target effects in RNase-H–  dependent 
or  RISC-dependent  activities. These  effects  may  arise  for 
example from binding of an oligonucleotide to incorrect tar-
get sequences that result in unwanted RNA cleavages, to 
miRNA-like effects of siRNA passenger strands, or to other 
Table 1  Selection of peptide–oligonucleotide conjugates and complexes used for mRNA targeting
mRNA targeting by antisense ONs
Peptide Conjugation strategy ON/ON analogue mRNA target Mechanism In vivo/in cells Reference
KLA Disulphide bond PNA Nociceptin/orphanin FQ 
receptor
Ribosome initiation 
block
In cells 52
F-3 Thiol-maleimide linker 2′-OMe/DNA/PS 
gapmer
Transcription factor Id1 RNase H-dependent 
mRNA degradation
In vivo 54
Pep-3 Complex formation PNA Cyclin B1 Ribosome initiation 
block
In vivo 55
Splice-redirecting ONs
Peptide Conjugation strategy ON/ON analogue pre-mRNA target Mechanism In vivo/in cells Reference
Variants of RX and Rβ Amide bond PMO β-globin interrupted 
Luciferase
Splice correction In cells 58
Penetratin, Tat, TP10, etc Disulphide bond PNA β-globin interrupted 
Luciferase
Splice correction In cells 42
R6-Peneratin Amide bond, thioacetyl 
linker
PNA β-globin interrupted 
Luciferase
Splice correction In cells 60
(RXR)4 Amide bond PMO β-globin interrupted 
Luciferase
Splice correction In cells 59
MPGα Complex formation 2’-OMe, LNA, 
PNA/DNA
β-globin interrupted 
Luciferase
Splice correction In cells 61
Pip2a Thioether PNA Dystrophin exon 23 Splice correction In vivo 64
CatLip Ethylene glycol linker, 
amide bond
PNA β-globin interrupted 
Luciferase
Splice correction In cells 65
Fatty acid-PNA-Arg9 Amide bond PNA β-globin interrupted 
Luciferase
Splice correction In cells 66
RGD Thiol-maleimide linker 2′-OMe/PS β-globin interrupted 
Luciferase
Splice correction In cells 67
Bombesin Thiol-maleimide linker 2′-OMe/PS β-globin interrupted 
Luciferase
Splice correction In cells 69
Stearyl-(RXR)4 Complex formation 2′-OMe/PS β-globin interrupted 
Luciferase
Splice correction In cells 70
Stearyl-TP10 Complex formation 2′-OMe/PS β-globin interrupted 
Luciferase
Splice correction In cells 49
PepFect14 Complex formation 2′-OMe/PS Dystrophin exon 23 Splice correction In vivo 72
(RXR)4, B-peptide Amide bond PMO Dystrophin exon 23 Splice correction In vivo 76
B-MSP Amide bond PMO Dystrophin exon 23 Splice correction In vivo 74
Pip5e Thioether PMO Dystrophin exon 23 Splice correction In vivo 75
Lys-n Amide bond PNA Phosphatase and 
tensin homologue 
exons
Splice correction In cells 77
PKKKRKV Amide bond PNA Intron in Eµ enhancer Eµ-dependent c-myc 
downregulation
In vivo 78
LNA, locked nucleic acid; mRNA, messenger RNA; ON, oligonucleotide; PMO, phosphorodiamidate morpholino oligonucleotide; PNA, peptide nucleic acid.Delivery of Antisense Oligonucleotides
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cellular effects such as immune activation. Peptide-mediated 
delivery often results in raised levels of cellular activity but 
it could also lead to increases in off-target effects (compare 
use of cationic liposomes to enhance delivery which have suf-
fered from the same problems). Whereas potency increases 
have been frequently demonstrated, off-target effects have 
rarely been measured systematically where peptide vectors 
have been used, and it is common to find only simple cell 
toxicity assays carried out. This limits the ability to compare 
methods effectively.
mRNA targeting by antisense oligonucleotides
There are only a few recent examples of peptide conjugates 
of oligonucleotides used for targeting mRNA (Table 1). A vari-
ety of CPPs of cationic or amphipathic origin disulfide-con-
jugated to a 12-mer PNA targeting the nociceptin/orphanin 
FQ receptor mRNA were studied for receptor downregula-
tion in cardiomyocytes.52 Among these CPPs, a repeating 
KLA  amphipathic  peptide  was  found  to  have  the  highest 
activity as a PNA conjugate in the absence of transfection 
agent, but no comparison was made with Arg-rich peptides. 
Interestingly,  there  was  found  no  correlation  of  bioactivity 
with the level of fluorescence uptake of labeled conjugates, 
confirming  previous  studies  with  peptide-PNAs.53  Further, 
receptor downregulation was improved through CPP conju-
gation by a relatively modest amount. The significant pheno-
typic activity for naked PNA and lack of clear quantitative link 
between phenotypic and genotypic antisense activity calls 
into question as to the extent mRNA antisense behavior is 
truly observed in this model.
Perhaps the most promising example of mRNA targeting 
involves  an  RNase-H–dependent  gapmer  2’-OMe/DNA/PS 
oligonucleotide that targets the transcription factor Id1 which 
was coupled to the F-3 31-mer peptide, a fragment of the 
high mobility group protein N2 which homes to neovessels in 
xenograft tumors.54 The conjugate showed substantial inhibi-
tion of tumor growth and metastasis in a mouse tumor xeno-
graft model. The peptide has been shown to bind to nucleolin, 
which is overexpressed on the surface of cancer cells and 
is subsequently transported into the nucleus. It is likely that 
the cationic nature of the peptides may result in aggrega-
tion of this conjugate to form nanoparticles in solution that 
leads to partial protection against degradation in serum and 
which perhaps improves cell and in vivo activity. Although 
delivery of the oligonucleotide conjugate by the homing pep-
tide  into  the  tumor  endothelium  and  dose-dependent  Id1 
Table 2.  Selection of peptide–-oligonucleotide conjugates and complexes used for anti gene targeting.
Gene targeting antisense ONs
Peptide Conjugation strategy ON/ON analogue Gene target Mechanism In vivo/in cells Reference
Poly Lys, Poly Arg Amide bond PNA Progesterone receptor DNA promoter binding In cells 79
Lys8 Amide bond PNA Huntingtin CAG repeat CAG repeat binding In cells 80
Penetratin Amide bond PNA supFG1 reporter gene Targeted supFG1 mutagenesis In vivo 16
ON, oligonucleotide; PNA, peptide nucleic acid.
Table 3  Selection of oligonucleotides and peptide–oligonucleotide conjugates used for miRNA blocking
miRNA-targeting ONs
Peptide Conjugation strategy ON/ON analogue miRNA target Mechanism In vivo/in cells Reference
— — LNA miR-122 miRNA binding In vivo 82
— — LNA/2′-OMe mixmer miR-122 miRNA binding In cells 19
— — LNA miR-21 miRNA binding In vivo 35
Lys4 Amide bond PNA miR-155 miRNA binding In vivo 22
Lys4 Amide bond PNA miR-122 miRNA binding In vivo 20
Tat Amide bond PNA Various miR sequences miRNA binding In cells 84
Peptide-mediated delivery of siRNAs
Peptide Conjugation strategy ON/ON analogue mRNA target Mechanism In vivo/in cells Reference
Tat, penetratin Disulphide bond siRNA P38α MAP kinase RISC activation In cells 86
SPACE Amide bond siRNA Interleukin-10, GAPDH RISC activation In vivo 87
RGD Thiol-maleimide linker siRNA Luciferase RISC activation In cells 88
Cholesterol-MPG-8 Complex formation siRNA Cyclin B1 RISC activation In vivo 90
CADY Complex formation siRNA Cyclin B1 RISC activation In vivo 91
Tat-LK15 Complex formation siRNA, shRNA Oncoprotein BCR-ABL RISC activation In cells 93
PepFect6 Complex formation siRNA HPRT1 RISC activation In vivo 94
Tat-DRBD fusion protein DRBD binding siRNA EGFR, Akt20 RISC activation In vivo 96
DRBD, double-stranded RNA binding domain; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LNA, locked nucleic acid; MAP, mitogen-activated 
protein; mRNA, messenger RNA; miRNA, microRNA; ON, oligonucleotide; PNA, peptide nucleic acid; RISC, RNA-induced silencing complex; shRNA; short 
hairpin RNA; siRNA, short interfering RNA.Molecular Therapy–Nucleic Acids
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protein knockdown was observed, both in cells and in vivo, 
surprisingly sequence- and dose-dependent downregulation 
of the corresponding Id1 mRNA was not reported, and thus 
there remains the question as to whether the biological activ-
ity observed was fully due to a sequence-specific antisense 
effect in this study. Nevertheless the strong in vivo activity 
observed is undeniable.
Among peptide-complex delivery strategies, a PEGylated 
amphipathic peptide Pep-3 was shown to mediate in vivo 
delivery of a PNA analogue oligonucleotide targeting cyclin 
B1 mRNA following intravenous injection through the forma-
tion of nanoparticles, and this resulted in reduction in rate 
of PC3 tumor growth.55 Pep-3 is a short 15-mer peptide that 
combines lysine/arginine-rich hydrophilic domains and tryp-
tophan/phenylalanine  hydrophobic  residues  to  form  stable 
complexes  with  the  antisense  oligonucleotide.  PEGylation 
was necessary for in vivo activity. In this case the effect is 
steric  block,  targeting  close  to  the  AUG  start  sequences, 
and  sequence-  and  dose-dependence  was  well  validated. 
A  20-fold  excess  of  Pep-3  over  oligomer  was  needed  for 
optimal cell delivery, whereas in vivo a layer of PEGylated 
peptide was added after initial complexation with unmodified 
peptide to enhance delivery. Further Pep derivatives have 
been developed for siRNA (see below).
Splice-redirecting oligonucleotides
Splicing redirection has been used extensively for measuring 
the efficacy of peptide-mediated cell delivery of oligonucle-
otides. This is due to a very convenient readout system where 
HeLa cells are stably transfected with a luciferase gene that 
is interrupted by a mutated β-globin intron.56 The mutation 
causes aberrant splicing of luciferase pre-mRNA, thus pre-
venting  translation.  Oligonucleotides  that  target  particular 
sequences at or close to the aberrant splice site (e.g., the 
“705” site) induce correct splicing and thus restore luciferase 
activity. A similar construct involves use of green fluorescent 
protein (GFP) in place of luciferase.57 The reliable positive 
readout and large dynamic range of the method allows the 
efficacy of different peptide vectors, conjugation strategies, 
and analogue types to be compared.58 The assay is well vali-
dated for many analogue types and delivery methods and 
sequence-specificity is not in doubt for such studies.
Further, the HeLa 705 assay has served as a model sys-
tem to help elucidate cellular uptake mechanisms.42 In gen-
eral, CPP conjugates are delivered through endocytosis and 
the CPP is believed to help the release from endosomes.7,59,60 
The uptake mechanisms of peptide-complexed oligonucle-
otides appear to be more diverse. Some peptide complex-
ing agents such as MPGα appear to utilize endocytosis,61 
whereas for other similar peptides a non-energy–dependent 
membrane-crossing pathway is proposed.62 To obtain splic-
ing redirection, the oligonucleotide must be delivered into the 
cell nucleus. Debate continues as to whether endocytosis or 
energy-independent mechanisms of delivery are optimal in 
such applications in terms of bioavailability, which is known 
to be poorly correlated with cell uptake.42,61
In  recent  studies  of  conjugates  of  charge-neutral  anti-
sense PNA and PMO, earlier Penetratin and Tat transduc-
tion  domains  have  now  been  replaced  by  Arg-rich  CPPs 
(Table 1). In the paradigm peptides, Arg residues are spaced 
by aminohexanoyl (Ahx or X) and/or β-alanyl (β) moieties to 
enhance hydrophobicity and proteolytic resistance in serum, 
such  as  (R-Ahx-R)4-Ahx-βAla  and  (R-Ahx-R-R-βAla-R)2-
Ahx-βAla called RXR4 and B-peptide respectively.36,63 The 
aminohexanoyl spacer in the R-Ahx-R motif was found to be 
optimal in the splicing-redirection assay among several other 
Table 4  Selection of peptide–oligonucleotide conjugates and complexes with antiviral and antibacterial activity.
Viral RNA targeting
Peptide Conjugation strategy ON/ON analogue mRNA target Mechanism In vivo/in cells Reference
B-peptide Amide bond PMO Protease TMPRSS2 pre 
mRNA
Splice blocking In cells   98
(RXR)4 Amide bond PMO L gene Ribosome initiation 
block
In vivo   99
(RXR)4 Amide bond PMO 5′-termini of viral genome Replication inhibition In vivo 100
(RXR)4 Amide bond, thioether PMO 5′-termini of viral genome Replication inhibition In vivo 101
(RXR)4 Piperazine linker PMO 5′-, 3′-termini of viral genome Replication inhibition In cells 102
Antibacterial activity of antisense ONs
Peptide Conjugation strategy ON/ON analogue Target Mechanism In vivo/in cells Reference
(RFF)3RXB Amide bond PMO acpP mRNA Ribosome initiation 
block
In vivo 106
(RXR)4 Amide bond PMO acpP mRNA Ribosome initiation 
block
In vivo 107
T-cell–derived CPP Amide bond PMO gyrase A mRNA RNase P activation In cells 108
(RXR)4 Amide bond PMO acpP mRNA Ribosome initiation 
block
In vivo 109
(KFF)3K Amide bond PNA acpP, ftsZ, murA, fabI mRNA Ribosome initiation 
block
In cells 110
(RXR)4, (KFF)3K Amide bond PNA rpoD mRNA Ribosome initiation 
block
In cells 111
CPP, cell-penetrating peptide; mRNA, messenger RNA; ON, oligonucleotide; PMO, phosphorodiamidate morpholino oligonucleotide; PNA, peptide nucleic acid.Delivery of Antisense Oligonucleotides
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spacers tried.59 Based on an initial discovery, that the addi-
tion of six Arg residues to the Penetratin peptide (R6Pen) 
resulted in significantly enhanced splicing redirection of PNA 
in HeLa 705 cells,60 a series of peptides known as Pip (PNA/
PMO  internalizing  peptides)  was  developed  that  include 
a hydrophobic core flanked by two Arg-rich regions, which 
when attached to PNA maintain good splicing redirection at 
submicromolar  concentrations,  yet  are  more  serum  stable 
and therefore usable in vivo.64
Another  recent  idea  is  to  add  a  second  chemical  moi-
ety such as a fatty acid to the end of an Arg-rich peptide 
to enhance delivery of the PNA conjugate.65 It was found 
that a decanoic acid was the optimal chain length to bal-
ance increased splicing redirection obtained with concurrent 
increases in cell toxicity as the chain length was extended. In 
a separate study, the addition of a C14 palmitoyl lipid chain 
to the free terminus of the PNA in a R9-PNA conjugate also 
increased  splice-redirecting  activity,  and  it  was  suggested 
that the increased activity was due to micelle formation.66
A conjugate between a 2′-OMe/PS antisense oligonucle-
otide and a bivalent RGD peptide, selectively targeting αvβ3 
integrin, was found to enter cells via receptor-mediated endo-
cytosis and was used for splicing redirection in melanoma 
cells.67 The RGD conjugate was found to enter cells by an 
endocytotic pathway distinct from that of naked oligonucle-
otide.68 Recently, a splice-redirecting antisense oligonucle-
otide was conjugated to bombesin peptide and its intracellular 
delivery  was  studied  in  gastrin-releasing  peptide  receptor 
expressing PC3 cells, which was transfected with a luciferase 
gene interrupted by an abnormally spliced intron. The results 
suggest  that  the  conjugate  enters  cells  via  a  process  of 
gastrin-releasing peptide receptor-mediated endocytosis fol-
lowed by trafficking to deep endomembrane compartments, 
leading  to  significantly  higher  luciferase  expression  com-
pared to unmodified oligonucleotides.69
The principle of using a peptide targeted to a cell surface 
receptor,  particularly  an  overexpressed  marker  on  cancer 
cells, is an excellent one. The issue lies in whether there is 
sufficient molecular recognition of a peptide conjugated to 
an  individual  oligonucleotide  to  deliver  enough  through  a 
specific receptor-mediated endocytotic pathway to provide a 
large boost in splicing redirection that has relevance in an in 
vivo setting. Demonstrations of quantitatively useful peptide-
mediated delivery in cells and in vivo are awaited eagerly.
Various types of stearylated peptide have been used to aid 
redirection of splicing using the noncovalent strategy. Stearyl-
RXR4 peptide at 5:1 ratio compared to 2′-OMe/PS oligonu-
cleotide was much more effective at luciferase upregulation 
than stearyl-Arg9 in HeLa 705 cells.70 More effort has gone 
into developing stearyl derivatives of the peptide Transpor-
tan 10 (TP-10) as nucleic acid delivery agents.49 In general, 
this class of stearylated peptide delivery agent seems to uti-
lize the endocytotic pathway.71 PF14, a peptide derivative of 
TP-10 containing pairs of ornithine as well as pairs of leucine 
residues,  showed  particularly  good  splicing  redirection  for 
2′-OMe/PS oligonucleotides both in the HeLa 705 cell assay 
as well as in exon skipping in mouse mdx muscle cells.72
CPP-aided splicing redirection is also a promising mecha-
nism for in vivo and therapeutic applications. The mdx mouse 
model of Duchenne muscular dystrophy (DMD), bearing a 
nonsense mutation in exon 23 of the dystrophin gene, is an 
important in vivo system for evaluation of peptide-delivery 
methods. Exon skipping with oligonucleotide analogues tar-
geting  exon  23  restores  the  transcript  reading  frame  and 
hence production of a shorter but active dystrophin protein. 
RXR4-PMO  and  B-PMO  conjugates  showed  dramatically 
improved dystrophin production, compared to naked PMO, 
following intravenous injection in the mdx mouse.27,63,73 PMO 
conjugated to a chimeric CPP comprising the B-peptide and 
a short muscle-specific peptide, known as B-MSP, showed 
higher activity in skeletal tissue in mdx mice than B-PMO.74 
An improved Pip series Arg-rich peptide (Pip5e) conjugated 
to  PMO  showed  enhanced  dystrophin  production  in  both 
skeletal muscles and heart using a single 25 mg/kg injec-
tion.75 This is a significant development, because, together 
with respiratory difficulties, cardiac deterioration is a major 
cause of death in DMD patients.
Peptide-PNA conjugates have also been used for in vivo 
antisense studies targeting DMD,76 as well as other targets. 
For example, it was reported recently that an amphipathic 
peptide covalently conjugated to a PNA was able to redirect 
splicing of the murine PTEN primary transcript in adipose 
tissue of male Balb/c mice after a low-dose intraperitoneal 
injection of 2.5 mg/kg.77 The study showed a clear depen-
dence of the levels of PNA antisense activity in adipose and 
other tissues depending on the peptide carrier sequence.
Enhancement of splicing redirection by PNA or PMO is 
clearly a well-suited application of covalently attached CPPs 
and potentially other peptide types, and further peptide vec-
tor development here is likely. For negatively charged splice-
directing oligonucleotides, good cell delivery enhancement 
has  been  observed  in  several  cases  by  complexing  with 
peptide vectors, but this has yet to translate into a sufficient 
advantage in vivo over naked oligonucleotides.
A cautionary tale serves as a reminder that not all intron-
targeting leads to clear interpretation of observed biological 
activity. For example, a PNA targeted to an intronic sequence 
in  a  severe  combined  immunodeficiency  mouse  model  of 
Burkitt’s lymphoma conjugated to a Lys-rich nuclear local-
ization signal peptide was shown to be effective in blocking 
tumor growth through multiple intravenous injections.78 This 
was a surprising result, because the Lys-rich peptide is very 
likely to be degraded rapidly in the circulation and thus insuf-
ficiently intact to act as an nuclear localization signal. Such 
peptide conjugation may instead alter the bioavailability of the 
PNA. No other peptide conjugates were examined. Further, 
the mechanism of action of the PNA in this case is obscure. 
The PNA was targeted to the Eµ enhancer sequence, which 
regulates  c-myc  overexpression.  PNA  binding  may  per-
haps alter RNA secondary structure to downregulate c-myc 
expression, rather than altering splicing patterns.
Gene targeting PNA
Three recent examples of antigene PNA (AgPNA) targeting 
are described (Table 2). AgPNAs conjugated to Lys-rich or 
Arg-rich short peptides have shown some effectiveness in 
targeting the progesterone receptor promoter DNA in breast 
cancer cells resulting in downregulation of receptor protein 
production, but to achieve this activity, cells needed to be 
treated with µmol/l concentrations of AgPNA for several days.79 Molecular Therapy–Nucleic Acids
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Further, it is not clear whether targeting was truly obtained at 
the DNA level or instead on short RNAs derived from tran-
scripts at the promoter site. A perhaps more promising target 
for PNA conjugated to the peptide Lys8 is the repeated CAG 
sequences in the mRNA of huntingtin to block mutant expres-
sion selectively in cells, which would be a potential approach 
to treat Huntington’s disease.80 However, there are alternative 
promising methods of targeting announced from the same 
laboratory involving use of other oligonucleotide analogues, 
siRNAs and miRNA mimics that may turn out to have higher 
allele-selectivity,81 and in vivo studies are awaited eagerly.
An interesting new application is the use of triplex-forming 
PNA conjugated with the classic CPP Penetratin to direct 
gene modification in the hematopoietic stem cells of mice, 
retaining unmodified differentiation capabilities.16 Sequence-
specific  gene  modification  was  also  observed  in  multiple 
somatic tissues following systemic administration, and also 
preserved  in  bone  marrow  and  spleen  of  recipient  mice 
following  transplantation  of  bone  marrow  from  Penetratin-
PNA–treated mice. This suggests that peptide–PNA conju-
gates might have good potential application for treatment of 
monogenic hematological diseases such as thalassemia and 
sickle cell anemia.
miRNA-targeting oligonucleotides (anti-miRs)
Most  of  the  anti-miR  oligonucleotide  types  utilize  2′-OMe, 
LNA or 2′-fluoro analogues usually as mixmers of more than 
one analogue type or with DNA (Table 3). In vivo applica-
tions all utilize PS linkages. Currently, there are no papers 
describing peptide delivery of such anti-miRs. As discussed 
above, it seems that some naked oligonucleotide analogues 
may have the ability not only to enter cells through endo-
cystosis but also can efficiently block miRNA activity with-
out need for any enhancement of transfection by peptide or 
other vectors.19,20,35,82,83 Thus it seems unlikely that peptide-
  mediated delivery will be of value for such oligonucleotide 
types.
In the case of PNA anti-miRs, just a few added Lys resi-
dues enhances cell uptake significantly,19,22 and a terminal 
Cys residue also adds to the uptake potential and anti-miR 
activity.20 A longer peptide is not required for activity19 but 
conjugation of an Arg-rich Tat peptide to PNA anti-mIRs has 
also shown efficient cell delivery while maintaining miRNA 
regulation activity in cell culture.84,85 In addition to CPPs, it 
seems likely that CPPs would be worth investigating here for 
the future development of PNA anti-miRs targeted to specific 
tissue types or to cancer cells.
Peptide-mediated delivery of siRNAs
Covalent  conjugation  of  siRNA  with  a  CPP  has  met  with 
limited success (Table 3). For example, reduction in mRNA 
expression was achieved only at high concentration of CPPs 
Tat or Penetratin conjugated to the 3′-end of the sense strand 
of siRNA,86 which is the most appropriate position for conjuga-
tion. An interesting peptide conjugated recently in this way is 
the cell and skin penetrating peptide called SPACE, identified 
by a phage display technique, which was evaluated for deliv-
ery of siRNA in vivo to two different targets, interleukin-10 
and GAPDH mRNAs. Conjugation of siRNA with the SPACE 
peptide  led  to  enhanced  skin-absorptive  properties  and 
knockdown of corresponding protein targets.87 It is hoped to 
use such conjugates to treat atopic dermatitis. Unfortunately, 
there was no experiment described showing knockdown at 
the mRNA level, which is required to be sure that the effects 
observed in cells and mice on protein reduction are entirely 
due to an siRNA-directed RNA cleavage.
Cyclic  RGD  peptides  have  been  investigated  as  tri-  and 
tetra-valent conjugates of siRNA and shown to bring about 
dose-dependent  reduction  of  reporter  luciferase  expression 
in human melanoma cells, but not the monovalent or divalent 
conjugates.88 This result demonstrates that, as with oligonucle-
otides, multivalency is likely to be necessary for conjugates of 
siRNA for sufficient effectiveness as a cell-targeting approach.
In general, noncovalent complex formation has been a more 
fruitful strategy to siRNA delivery (Table 3).89 An amphipathic 
cholesterol-functionalized peptide carrier, Chol-MPG-8, was 
shown capable of complexing siRNA-targeting cyclin B1 and 
to lead to tumor growth reduction after intravenous injection 
in a PC-3 cancer model.90 The high stability of Chol-MPG-8–
based nanoparticles and the slow release of the siRNA within 
cells allowed the use of low concentrations of siRNA. A pep-
tide named CADY was also reported by the same research 
group to bring about inhibition of PC3 tumor growth when 
complexed with siRNA.91 CADY adopts a helical conforma-
tion within cell membranes, where charged amino acids are 
exposed on one side of the helix and tryptophan residues, 
found essential to good cellular uptake, are on the other side. 
Importantly,  CADY–siRNA  complexes  were  shown  to  bind 
to phospholipids on biological membranes via electrostatic 
interactions and enter cells by energy-independent translo-
cation  thereby  bypassing  the  endosomal  pathway.46,62,92  A 
fusion peptide of Tat (49-57) and a membrane lytic peptide 
LK15 was shown to form complexes with both short hairpin 
RNA and siRNA targeting BCR-ABL oncoprotein mRNA, but 
the short hairpin RNA induced a more stable silencing of the 
gene target in K562 chronic myeloid leukemia cells compared 
to siRNA complexes.93
Stearylated peptide vectors have also been used success-
fully to deliver siRNA. A TP10-derived lipopeptide (PF6) was 
designed to aid endosomal release through attachment of 
four pH titratable trifluoromethylquinoline moieties to a lysine 
side chain of TP10. PF6 was shown to form nanoparticles 
with siRNA and knockdown HPRT1 mRNA production in a 
range of cell types as well as in kidney, lung, and liver of mice 
upon tail vein infusion at 1 mg/kg.94
An alternative peptide–siRNA complexation approach uti-
lizes a recombinant fusion of the HIV Tat protein PTD with a 
double-stranded RNA binding domain (DRBD) that binds to 
siRNA and neutralizes its negative charges. The PTD-DRBD 
peptide vector has shown excellent cellular delivery of siRNA 
into  various  primary  and  transformed  cells.95  PTD-DRBD 
was used to package two siRNAs simultaneously (against 
EGFR and Akt20) to induce tumor-specific apoptosis in a 
glioblastoma model after intracerebral injection, and to also 
substantially  increase  mouse  survival.96  The  PTD-DRBD 
peptide is now being developed industrially, but its very large 
size makes it unsuitable for chemical synthesis. Further the 
general applicability for siRNA delivery in vivo, especially for 
systemic use, is in doubt in the absence of further examples 
of efficacy.Delivery of Antisense Oligonucleotides
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viral RNA targeting
Although there are no examples of peptides being used 
for delivery of negatively charged oligonucleotides as anti-
viral agents, peptide conjugates of charge-neutral PNA and 
PMO have been investigated for some years. Peptide-PMO 
antiviral applications up to 2007 include targeting of Den-
gue virus, Cocksackievirus, Ebola, and Marburg viruses for 
example and are reviewed in reference 36. Despite reassur-
ing results that PNA-peptides targeted to the HIV-1 trans-
activation responsive element are nontoxic in mice at high 
(300 mg/kg) doses,97 antiviral development seems recently 
to have ceased for PNA peptides. By contrast, RXR4 and 
B-peptide conjugates of PMO oligonucleotides have recently 
shown high antiviral activities both in cell culture and in vivo 
in various systems (Table 4). For example, P-PMO conju-
gates  interfered  with  splicing  of  hemagglutinin-activating 
protease TMPRSS2 pre-mRNA and suppressed viral titers 
by two to three log10 units in Influenza A cultures.98 Similarly, 
RXR4-PMOs blocked viral replication of human respiratory 
syncytial viruses both in cells and in BALB/c mice.99 Here, the 
PMO sequence was targeted to the start of the coding region. 
Interestingly, there was also reduction in lung viral titers even 
with treatment of mice 3 hours after infection, but not 8 hours 
after infection. This suggests the PMO needs to be present in 
the cell soon after infection if it is to have an impact on virus 
production.
Particularly promising results have been obtained in vivo 
in pre- and post-infection P-PMO treatment of pigs infected 
with  porcine  reproductive  and  respiratory  syndrome  virus 
both in reducing viremia and interstitial pneumonia.100 RXR4–
PMO  conjugates  were  also  seen  to  substantially  improve 
antisense activity in vivo over naked PMO in protection of 
mice upon infection with West Nile virus or coronavirus by 
targeting to specific viral RNA sites involved in translation or 
replication.101,102
Overall, the P-PMO approach is very promising, but it also 
must compete with other antiviral approaches including use 
of PMO analogues with cationic groups within the PMO as 
currently being exploited by AVI Biopharma (Bothell, WA).
Antibacterial activity of antisense PNA and PMO
Increasing multidrug resistance in bacteria and the difficulties 
in discovery of new small molecule antibiotics have prompted 
consideration of new strategies such as gene targeting by 
PNA and PMO for treating bacterial diseases. However, the 
delivery of PNAs into bacterial cells has proved to be prob-
lematic. Although some CPPs may themselves have intrinsic 
antimicrobial  activity,103  peptide-mediated  delivery  of  anti-
sense PNA and PMO targeting specific essential bacterial 
genes was suggested more than 10 years using peptide–PNA 
conjugates104 and has shown recent promise as an antibacte-
rial strategy (Table 4). In particular, Arg-rich peptides conju-
gated to PMO are able to penetrate the cell outer membrane 
and display gene-specific antibiotic activity in gram-negative 
bacteria.105 The peptide–PMO conjugates are able to reduce 
bacterial blood titers and increase survival in Escherichia coli 
infected mice.106,107 Very recently, a novel 22-residue Arg-rich 
peptide derived from human T cells, when conjugated to PMO 
targeting GyrA was able to induce broad range bacterial cell 
killing at concentrations much lower than required for activity 
by other Arg-rich peptide-PMOs.108 The higher than perhaps 
anticipated activity is attributed to non-gene–specific RNA 
targeting of the P-PMO in addition to a gene specific effect, 
suggesting partial bacteriocidal activity plays an important 
role here. Interestingly, PMO containing positive charges in 
the PMO backbone also have antisense activity but did not 
achieve the same efficiency as peptide-conjugated PMO.109
PNAs conjugated to a Lys-rich peptide have also been used 
successfully to validate essential gene targets in Escherichia 
coli by studying the relationship between decrease in mRNA 
expression  and  growth  rate  decline.110  Further,  peptide-
conjugated PNA targeting rpoD, a gene essential for bac-
terial growth, showed broad inhibition in multidrug-resistant 
Escherichia  coli,  Salmonella  enterica,  Klebsiella  pneumo-
niae, and Shigella flexneri both in cells and in vivo.111
The variety of recent promising results shows that peptide-
mediated delivery of PMO and PNA holds promise for further 
drug development against multidrug-resistant bacteria.
POLYMER, LIPOSOMAL, AND EXOSOME DELIvERY 
METHODS INvOLvING PEPTIDES
Peptide-conjugated polymers
Synthetic  and  naturally  occurring  cationic  polymers  rep-
resent a large group of carriers for nucleic acids. Although 
initially developed for the purpose of gene delivery, numer-
ous reports have affirmed their utility in oligonucleotide deliv-
ery. These linear or branched polymers range from the first 
discovered poly-L-lysine (PLL), to the most frequently used 
polyethyleneimine (PEI).112,113 They share the properties of 
condensing oligonucleotides into small particles (polyplexes) 
that facilitate cellular uptake via endocytosis. However, their 
delivery efficiencies and toxicities vary significantly. PEI has 
been produced in particular in an assortment of structural 
variants.114
A major drawback with use of PEI and many other cationic 
polymers is their non-biodegradable nature, which raises tox-
icity concerns.115 Furthermore, their efficiencies have been 
poor in vivo in many cases, due to unwanted interactions with 
serum components.115,116 Polyethylene glycol (PEG) linkers of 
different sizes have been included in PEI polymers in order 
to prolong the circulation time in blood (reviewed in ref. 117). 
Although such PEGylation significantly stabilizes polyplexes, 
it unfortunately often results in lower potency, due to inad-
equate  cellular  uptake  and  poor  endosomal  escape.117,118 
Another strategy for stabilization of polyplexes involves use of 
hydrophobic modifications. For example, partial modifications 
of amines in PEI with tyrosine stabilize polyplexes significantly 
increases transfection of both siRNAs and splice-redirecting 
2′-OMe  oligonucleotides.119,120  Analogously,  modification  of 
polyamines with hydrophobic acrylates results in stabilization 
of cores for highly efficient siRNA and 2′-OMe anti-miR deliv-
ery in vivo.121,122
Peptide modifications of cationic polymers have been used 
successfully  to  either  improve  tissue  targeting  or  overall 
delivery efficacy and to decrease the required dose. Pioneer-
ing work from the laboratory of Ernst Wagner showed that 
PEI-mediated gene transfer can be improved dramatically by 
incorporation of receptor-targeting peptide ligands (reviewed 
in ref. 117,123,124).Molecular Therapy–Nucleic Acids
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Many other groups have capitalized on this peptide/cationic 
polymer strategy to improve gene delivery profoundly.125,126 
Surprisingly, examples of use of targeting peptides and CPPs 
to enhance polyplex delivery of oligonucleotides have been 
sparse. In one study. Tat peptide was conjugated to PEGy-
lated PEI which, when complexed with 2′-OMe oligomers and 
injected intramuscularly into mdx mice, improved exon skip-
ping of dystrophin pre-mRNA.127
Several  successful  studies  on  siRNA  delivery  have  been 
reported. Schiffelers et al. utilized the integrin-binding peptide 
RGD attached to PEGylated PEI for delivery of siRNA targeting 
VEGF-R in tumor-bearing mice.128 Similarly, Wang et al. conjugated 
a bombesin peptide via a PEG spacer to a free thiol group in an 
amphiphilic polymer N-(1-aminoethyl)iminobis[N-(oleicyl-cysteinyl-
histidinyl-1-aminoethyl)propionamide] (EHCO) to target bombesin 
receptors overexpressed on various cancer cells.129 The siRNA/
functionalized polymer complex was shown to efficiently promote 
RNA interference responses in cells and systemic administration 
of anti-HIF-1α siRNA with bombesin-containing EHCO displayed 
significant advantage over nontargeted polymer in inducing target 
reduction in a xenograft model of human glioma.
PEGylated transferrin peptide combined with oligoethyleneimine 
was able to deliver siRNA highly efficiently into neuroblastoma-
bearing mice.130 Further, an elegant demonstration of recep-
tor-specific  uptake  of  defined  folate-PEG-siRNA  conjugates 
together with a structurally defined polycation was shown in use 
of such complexes for specific gene silencing.131
Instead  of  targeting  peptides,  the  Wagner  group  has 
obtained improved endosomal escape by inclusion of fuso-
genic peptides. In the initial study, PEGylated polylysine/PEI 
was covalently linked to the endosomolytic peptide, melittin. 
Since melittin possesses lytic properties at both neutral and 
low pH, amines within the peptide were masked by reac-
tion  with  dimethylmaleic  anhydride  (DMMA).  Dimethylma-
leic groups are removed at low pH within endosomes, thus 
exposing  the  lytic  peptide.  Polycation-PEG-DMMA-melittin 
conjugates  were  mixed  with  siRNAs  to  form  polyplexes 
that efficiently induced an RNA interferene response in cell 
culture.132  In  a  further  study  with  the  same  components, 
a cysteine residue was incorporated into the PLL to allow 
disulfide formation with an siRNA containing a 5′-thiolated 
sense strand. Such conjugates were almost as efficient as 
polyplexes and displayed reduced cytotoxicity.133
Another  important  example  of  peptide/polymer  combi-
nations  is  a  cyclodextrin  containing  polymer  (CDP)-based 
system, which so far is the only platform reported for RNA 
interference delivery in humans.134 CDP is a short polycation 
that assembles with nucleic acids (e.g., siRNA) via electro-
static interactions. In order to facilitate endosomal escape, 
imidazole groups were incorporated on the ends of the poly-
mer to act as proton sponges. For systemic delivery, the poly-
mer was stabilized by inclusion of surface-functionalized PEG 
moieties. In contrast to other polymeric delivery systems, the 
CDP approach relies on noncovalent incorporation of PEG 
via conjugation to adamantane, a small molecule that forms 
a  high  affinity  inclusion  complex  with  cyclodextrin.  Finally, 
in order to confer tissue targeting to solid tumors, the sur-
face of CDP was coated with adamantane conjugated to the 
transferrin ligand for targeting of transferrin receptors that are 
expressed abundantly on the surface of tumors.135
Liposomal nanovectors with peptide ligands
Many common cationic liposomal vectors used for nucleic acid 
delivery in cell culture, such as lipofectin or lipofectamine, are 
not suited for in vivo use, because of their sensitivity to serum 
proteins and their toxicity.136,137 Surface functionalization with 
inert hydrophilic polymers such as PEG has improved in vivo 
use of such vectors (reviewed in ref. 138), but PEGylation 
decreases cell delivery due to poor membrane interactions 
and poor endosomal escape.118,139 New lipid formulations that 
include peptides have broadened the repertoire of liposomes 
used for oligonucleotide delivery. In particular, the inclusion 
of Arg-rich CPPs on such liposomes has proven as a potent 
strategy to enhance transfections.10,138 In a recent example 
of peptide-mediated siRNA delivery, liposomal nanoparticles 
that  are  octaarginine-modified  was  used  to  encapsulate 
siRNA and to silence an endogenous gene in liver cells as 
well as in vivo at low concentrations of siRNA (25 µg/mouse) 
using a single dose, without evidence for liver toxicity.140 In 
another example, cationic liposomes were modified by a chi-
meric peptide containing 16 lysine residues and a short mul-
ticell targeting peptide Y and used to deliver siRNA against 
luciferase and GAPDH targets.141
A further example of rational liposome design is the multi-
functional envelope-type device (MEND) system.10 In the proto-
type MEND, oligonucleotides are condensed with polycations 
(protamine) and wrapped by a lipid envelope containing cat-
ionic, anionic, and helper lipids, such as dioleoyl-sn-glycero-
3-phosphoethanolamine  (DOPE)  that  improves  endosomal 
escape. In addition to surface modification with PEG, peptide 
delivery vectors have been incorporated on to the surface of 
such liposomes using a stearylated peptide that spontaneously 
inserts into the lipid membrane. Novel versions of MEND contain 
cleavable PEG linkers as well as targeting peptides for specific 
receptors or fusogenic peptides, in order to confer targeting of 
specific tissues and controlled release of encapsulated cargoes 
(reviewed in ref. 118). MEND has been efficiently exploited for 
delivery  of  unmodified  single-stranded  antisense  oligonucle-
otides in cells as well as siRNAs both in cells and ex vivo in 
dendritic cells.142–144 Very recently, an even more sophisticated 
MEND  system  was  efficiently  utilized  for  systemic,  targeted 
delivery of siRNA to tumors.145
Similar liposomal delivery systems have been developed for 
drug delivery by Torchillin and colleagues, where the surface 
has been decorated with the CPP Tat.138 To incorporate the 
Tat peptide in a controlled manner, it was covalently linked to 
the anionic lipid phosphatidic acid that spontaneously inserts 
into liposomes. Such liposomes have been used primarily for 
targeted delivery of plasmid DNA to tumors, but have also 
been shown to be effective for siRNA delivery.146 CPPs have 
also been used in conjunction with conventional liposome-
based transfection agents and synergistic effects reported for 
the delivery of splice redirecting 2′-OMe oligomers.147
Peptide-functionalized exosomes
Practically all nanoparticle vectors for oligonucleotide deliv-
ery have been developed for targeting liver or tumors. Devel-
opment of efficient carriers for crossing of other biological 
barriers, such as the blood-brain barrier, is in its infancy. In 
addition to synthetic nonviral vectors, which still retain inher-
ent risks of raising an immune response or causing systemic Delivery of Antisense Oligonucleotides
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toxicity in vivo, an alternative biologically derived vector has 
recently been proposed that makes use of naturally occurring 
membrane vesicles secreted by most cells and found in all 
body fluids, which are thought to be key mediators of infor-
mation transmission between cells in the body.148
A subgroup of such vesicles are termed exosomes, which 
have been shown recently to contain various RNA species. 
They exert their biological effects either by directly activating 
cell surface receptors on target cells or by transferring pro-
teins from the cell of origin to the recipient.149 Furthermore, 
numerous studies suggest that exosomes, which are derived 
from  the  endolysosomal  pathway  and  have  a  diameter  of 
40–120 nm, play a crucial role in the horizontal transfer of 
RNA to neighboring or distant recipient cells.150,151 Of particu-
lar interest is their ability to deliver miRNAs into recipient cells 
to induce gene silencing.152,153 Such properties indicate that 
they would be highly suitable candidates for oligonucleotide 
and siRNA delivery.
Wood et al. recently provided the first proof-of-concept study 
for delivery of exogenous siRNA using such exosomes.154 
Immature  dendritic  cells  were  chosen  as  source  for  exo-
somes,  because  they  lack  T-cell  activators  and  are  thus 
immunologically inert.155 In order to confer targeting of exo-
somes to the brain, dendritic cells were transfected with a 
plasmid expressing an exosomal protein Lamp2b fused to 
a  brain-specific  peptide,  rabies  virus  glycoprotein-derived 
peptide (RVG),156 which becomes presented at the surface 
of  exosomes.  RVG-targeted  exosomes  were  subsequently 
purified from cell cultures and loaded with exogenous siRNA 
by  electroporation.  Systemic  delivery  of  GAPDH  targeting 
siRNA with RVG-exosomes resulted in specific knockdown of 
GAPDH in several regions of mouse brain such as cortex and 
striatum. The potency of RVG-exosomes was tested by deliv-
ery of BACE-1 siRNA (targeting the enzyme β-secretase), 
which resulted in significant and specific target knockdown 
(60%) in the mouse brain cortex. This knockdown led to a 
reduction  in  the  extracellular  accumulation  of  Aβ1-42,  the 
toxic amyloid species produced by BACE-1 that is implicated 
as a cause of Alzheimer’s disease. No toxicity or immuno-
genicity was observed, even after repeated administration, a 
prerequisite for many disease applications.
PHYSIOLOGICAL ASPECTS OF PEPTIDE-MEDIATED 
OLIGONUCLEOTIDE AND siRNA IN VIVO DELIvERY
Crucial to the clinical application of peptide-based oligonu-
cleotide and siRNA therapies is the tailoring of such drugs 
for  whole-body  distribution,  in  order  to  maximize  specific 
tissue targeting while minimizing induced toxic or immune 
responses. In vivo biodistribution data can be derived either 
by the assessment of an induced biological affect, by the 
detection of a directly labeled bio-cargo, or by use of a trans-
genic animal reporter system, yet each method has cave-
ats in their use. Measurement of an induced biological affect 
is restricted to those tissues where the transcript targeted 
by the oligonucleotide or siRNA is expressed, for example, 
using dystrophin exon skipping and protein restoration as a 
read-out in the mdx mouse model.75 Fluorescent molecules 
or radioactive isotopes have been used successfully to label 
and follow the biodistribution of peptide conjugates of bio-
cargoes  such  as  PNA.157  However  it  is  important  to  note 
that where the peptide part only is labeled, label detection 
may not always correlate with the location of the bioactive 
cargo. For example, a recent report of an N-terminally FITC-
labeled B-PMO having crossed the blood-brain barrier and 
reaching Purkinje cells in wild-type mice should be viewed 
with caution until confirmed by other methods.158 An EGFP-
654 transgenic mouse model that ubiquitously expresses an 
aberrantly spliced EGFP-654 pre-mRNA reporter gene has 
been used to assess functional biodistribution of B-PMO.159 
However, such distribution assessments might not reflect the 
potential of a peptide-PMO to influence a disease pathology, 
whereas in an animal model of a disease such as DMD this 
becomes less of an issue. Nevertheless the use of all three of 
these techniques together can provide valuable information 
in building a view of how a peptide affects biodistribution of 
an oligonucleotide cargo.
An important parameter in systemic delivery is the route of 
administration (i.e., intravenous, intraperitoneal, subcutane-
ous, oral or nasal) in order to find the best biodistribution pat-
tern for the particular application, but also to obtain optimal 
safety profiles.160 The efficacies of the delivery routes depend 
on the specific peptide ligand as well as the cell-targeting 
requirements of the studied disease, and must be balanced 
against the toxicology profile of the peptide-modified cargo. 
Very few direct comparisons of delivery routes have been 
published,  but  for  B-PMO  conjugates  for  example,  higher 
efficiencies have been achieved via the intravenous delivery 
route compared to the subcutaneous route.159
Toxicity and unwanted immune activation by peptide con-
jugates of oligonucleotides and siRNA need to be carefully 
assessed  in  each  case.  For  example,  Penetratin–siRNA 
conjugates  showed  innate  immune  activation  following 
intratracheal administration.161 By contrast, Penetratin–PNA 
conjugates did not induce an immunogenic response after 
intraperitoneal delivery and were well tolerated in mice at 
100 mg/kg.97 Although CPPs do have potential to stimulate 
unwanted  immunological  responses,  their  small  size  and 
the use of analogues has reduced this risk significantly. For 
example, no immune response has been seen to date for 
B peptide-PMO162 and there are no reports of any peptide-
PMO or peptide–PNA conjugate to date inducing a signifi-
cant response.
The nature and levels of in vivo toxicity are not currently 
well understood for peptide conjugates of oligonucleotides or 
for peptide-based vector delivery routes, and there are very 
few published in vivo studies, probably because of commer-
cial sensitivity of such data. However, peptide-PMO acts as 
a good case study. Here the PMO cargo has an amazingly 
good safety profile in animals and in many clinical trials.37,163,164 
Thus the safety profile of a P-PMO conjugate will depend 
almost entirely upon the specific peptide sequence and is 
assessed in the context of the therapeutic dose required in 
a particular clinical setting. Amantana et al. investigated the 
safety profile in rats of an anti-c-myc PMO conjugated to the 
RXR4 CPP. Although lower doses of the CPP-PMO were well 
tolerated (15 mg/kg), adverse events such as lethargy, weight 
loss, and elevated blood urea nitrogen and serum creatinine 
levels were reported at much higher doses (150 mg/kg), with Molecular Therapy–Nucleic Acids
Delivery of Antisense Oligonucleotides
Järver et al
14
a lethal dose reported as 400 mg/kg.165 Toxicity has also been 
reported in non-human primates following a preclinical study 
with the B-PMO peptide conjugate developed by AVI Bio-
Pharma. Dose-dependent toxicity was observed in healthy 
Cynomolgus monkeys with four weekly intravenous injections 
of 9 mg/kg, causing tubular degeneration in the kidneys (AVI 
BioPharma website www.aviobio.com).63 No toxic effect was 
observed at higher doses in mdx mice, thus highlighting that 
the P-PMO toxicity threshold varies between species. Although 
lower  toxic  thresholds  have  been  reported  elsewhere,  com-
parisons between studies assessing the use of CPPs to deliver 
non-oligomers are problematic, because the effect of the cargo 
cannot be distinguished from that of the CPP.166
In another useful study, Wancewicz et al. have reported 
acute toxicity in mice for a PNA containing nine additional Lys 
residues when dosed at 10.5 µmol/kg at three times a week 
for 2 weeks.77 Similarly a PNA conjugated to an amphipathic 
peptide containing Lys, Leu, and Ala residues showed severe 
nephrotoxocity, with profound proximal tubule necrosis at 40 
mg/kg dose, whereas a PNA conjugate with mostly Arg and 
homoArg residues did not show such toxicity at this dose. 
Interestingly, the tissue distributions of these two peptide-
PNAs differed widely, with the latter Arg-rich conjugate show-
ing good splicing redirection in adipose tissue (the targeted 
organ) even at a low dose of 2.5 mg/kg.77
Thus, although immunogenicity seems unlikely to be an 
issue for most small peptides as oligonucleotide conjugates, 
toxicity profiles need to be evaluated carefully on a case by 
case basis to establish an effective yet safe dosing regimen 
in humans. There is clearly an important need to determine 
the exact nature of peptide-induced toxicity patterns, along-
side the development of further peptide modifications, if such 
peptide applications are to reach the clinic.
CLINICAL PERSPECTIvES OF PEPTIDE-MEDIATED 
DELIvERY OF NUCLEIC ACIDS
Efforts  to  translate  synthetic  peptides  conjugates  or  com-
plexes of oligonucleotides and siRNA to treat human disease 
have recently stepped up. Many of the polymeric, liposomal, 
and other nanovectors involving peptides have shown great 
promise  for  delivery  in  cell  culture  and  in  animal  models. 
However, there are no examples yet of any of these reach-
ing  clinical  trials  apart  from  the  application  involving  the 
human transferrin protein used in siRNA particle formation 
which was recently reported in the clinic.134 The application 
of  short  peptides  in  siRNA  delivery  applications  needs  to 
overcome remaining obstacles of reproducible and validated 
manufacture of the overall vectors. In addition, there needs 
to be better control of off-target effects that lead to toxicities. 
Peptide-based ligands displayed on such vectors are bound 
to feature more in clinical development in the near future and 
these are already helping to gain greater tissue and target-
ing specificity. It is hoped that further preclinical development 
studies here will be published soon to help move such thera-
pies to the clinic as rapidly as possible.
Therapeutic  approaches  for  neuromuscular  disorders 
currently  lead  the  way  in  clinical  development  of  peptide-
mediated  delivery.  Repeat  systemic  dose-escalation  stud-
ies of naked PMO and 2′-OMe/PS oligonucleotides having 
been completed recently in DMD patients and further dose-
escalations  studies  planned37,167  (current  trials  reviews  in 
ref. 168), while recruitment for a clinical trial to treat spinal 
muscular  atrophy  is  underway  (clinicaltrials.gov  identifier: 
NCT01494701),  which  is  another  neuromuscular  disease 
where peptide-conjugated PMO is likely to be applied.
Recently there has been a concerted effort to evaluate the 
potential of CPPs and other peptides in some multi-systemic 
neuromuscular disorders. For example, our laboratories are 
currently involved in multi-center development of a peptide-
PMO to treat DMD, based on initial evaluations in the mdx 
mouse as a model, and further preclinical therapeutic studies 
are underway to supplement data already published.75,159,165 
Here,  a  lead  Pip  peptide  conjugated  to  PMO  has  shown 
excellent dystrophin production in cardiac muscle, a tissue 
previously  shown  to  take  up  naked  antisense  oligomers 
poorly, in addition to in skeletal muscles.75 However, evidence 
of induced renal toxicity in monkeys for the earlier B-PMO 
lead63 has highlighted the needs for caution and for obtaining 
a deeper understanding regarding possible toxic side effects 
of cationic CPPs.
It seems likely that the simplicity of the peptide conjugation 
approach and the ability to apply the principle of a steric-block-
ing approach across a broad range of neuromuscular and neu-
rodegenerative diseases will likely drive the clinical development 
of peptide conjugates of oligonucleotides and their analogues 
forward for several years to come. New examples of preclinical 
development are expected soon in several of such diseases and 
there is great hope that one or more of these conjugates will 
make it to the clinic in the near future.
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